Biotech Prima Biomed has released positive results from a clinical trial of its lead product to treat metastatic breast cancer.
Prima said on Thursday that the initial data from the trial confirmed that its IMP321 product was safe and well tolerated in patients when used in combination with chemotherapy.
Shares in Prima Biomed were 0.1 cent, or 2.7 per cent, higher at 3.8 cents at 1019 AEDT.
